CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • TNYA Dashboard
  • Financials
  • Filings
  • ETFs
  • Insider
  • Institutional
  • Shorts
  • News
  • Patents
  • Reddit

Tenaya Therapeutics (TNYA)

Company Profile
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic cardiovascular disorders, as well as for more prevalent heart conditions, through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. For more information, visit www.tenayatherapeutics.com.

Company profile

Ticker
TNYA
Exchange
NASDAQ
Employees
Incorporated
Delaware
Location
California
Fiscal year end
Dec 31
Sector
Professional, Scientific, and Technical Services > Research and Development in Biotechnology
Industry (SIC)
Biological Products, (No Diagnostic Substances)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Bio-Techne • Ginkgo Bioworks ...
SEC CIK
0001858848
Corporate docs
Articles of Incorporation & Bylaws
Underwriting Agreements
Indentures
Material Contracts & Credit Agreements
IRS number
813789973

TNYA stock data

Analyst ratings and price targets

Last 3 months
Current price
Average target
$20.67
Low target
$13.00
High target
$28.00
Morgan Stanley
Maintains
Overweight
$13.00
24 Jan 23
Chardan Capital
Maintains
Buy
$28.00
11 Nov 22
Canaccord Genuity
Initiated
Buy
$21.00
8 Nov 22
Latest filings (excl ownership)
View all
8-K
Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors
7 Dec 22
8-K
Tenaya Therapeutics Announces Pricing of Public Offering
17 Nov 22
424B5
Prospectus supplement for primary offering
17 Nov 22
424B5
Prospectus supplement for primary offering
16 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
10 Nov 22
EFFECT
Notice of effectiveness
18 Aug 22
424B5
Prospectus supplement for primary offering
17 Aug 22
CORRESP
Correspondence with SEC
15 Aug 22
UPLOAD
Letter from SEC
12 Aug 22
Latest ownership filings
View all
4
Change in insider ownership
23 Jan 23
4
DAVID V GOEDDEL
23 Jan 23
4
Change in insider ownership
19 Jan 23
4
DAVID V GOEDDEL
19 Jan 23
4
Deepak Srivastava
9 Dec 22
4
Amy L. Burroughs
7 Dec 22
3
Amy L. Burroughs
7 Dec 22
SC 13D/A
Casdin Capital, LLC
7 Dec 22
SC 13D
COLUMN GROUP III, LP
1 Dec 22
SC 13D/A
Casdin Capital, LLC
28 Nov 22

Financial summary

Financial statements Chart TNYA financial data
Quarter (USD) Sep 22 Jun 22 Mar 22 Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 34.89 mm 34.89 mm 34.89 mm 34.89 mm 34.89 mm
Cash burn (monthly) (no burn) 6.89 mm 10.43 mm 9.77 mm 2.40 mm
Cash used (since last report) n/a 26.88 mm 40.67 mm 38.09 mm 9.34 mm
Cash remaining n/a 8.02 mm -5.78 mm -3.19 mm 25.55 mm
Runway (months of cash) n/a 1.2 -0.6 -0.3 10.7

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

TNYA institutional ownership history Ownership history
13F holders Current Prev Q Change
Total holders 66 50 +32.0%
Opened positions 21 6 +250.0%
Closed positions 5 6 -16.7%
Increased positions 20 11 +81.8%
Reduced positions 9 21 -57.1%
13F shares Current Prev Q Change
Total value 275.68 mm 381.62 mm -27.8%
Total shares 43.02 mm 45.55 mm -5.5%
Total puts 24.10 k 0.00 NEW
Total calls 0.00 0.00
Total put/call ratio Infinity – –
Largest owners Shares Value Change
Column Group Iii 9.40 mm $178.14 mm 0.0%
Column 9.40 mm $27.26 mm 0.0%
Casdin Capital 3.59 mm $10.40 mm 0.0%
FMR 3.13 mm $9.06 mm -43.5%
RTW Investments 2.46 mm $7.13 mm 0.0%
BLK Blackrock 2.44 mm $7.08 mm -0.9%
T. Rowe Price 2.11 mm $6.13 mm -37.2%
Regents Of The University Of California 1.63 mm $4.72 mm NEW
Ra Capital Management 1.60 mm $4.65 mm -54.9%
T. Rowe Price Investment Management 1.56 mm $4.54 mm NEW
Largest transactions Shares Bought/sold Change
FMR 3.13 mm -2.40 mm -43.5%
Ra Capital Management 1.60 mm -1.95 mm -54.9%
Regents Of The University Of California 1.63 mm +1.63 mm NEW
T. Rowe Price Investment Management 1.56 mm +1.56 mm NEW
T. Rowe Price 2.11 mm -1.25 mm -37.2%
Deep Track Capital 0.00 -483.84 k EXIT
STT State Street 0.00 -390.42 k EXIT
Commodore Capital 0.00 -357.70 k EXIT
Citadel Advisors 217.34 k +168.38 k +343.9%
Renaissance Technologies 166.20 k +166.20 k NEW
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

TNYA insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
19 Jan 23 David V Goeddel Common Stock Buy Acquire P Yes No 2.4979 69,739 174.20 k 9,870,274
19 Jan 23 Column Group Iii GP Common Stock Buy Acquire P Yes No 2.4979 69,739 174.20 k 9,870,274
18 Jan 23 David V Goeddel Common Stock Buy Acquire P Yes No 2.5163 135,688 341.43 k 9,800,535
18 Jan 23 Column Group Iii GP Common Stock Buy Acquire P Yes No 2.5163 135,688 341.43 k 9,800,535
17 Jan 23 David V Goeddel Common Stock Buy Acquire P Yes No 2.4947 49,463 123.40 k 9,664,847
17 Jan 23 Column Group Iii GP Common Stock Buy Acquire P Yes No 2.4947 49,463 123.40 k 9,664,847
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro
Morgan Stanley Maintains Overweight on Tenaya Therapeutics, Lowers Price Target to $13
24 Jan 23
Morgan Stanley analyst Matthew Harrison maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Overweight and lowers the price target from $15 to $13.
Tenaya Therapeutics, Clear Channel Outdoor And These 2 Penny Stocks Insiders Are Aggressively Buying
20 Jan 23
The Dow Jones closed lower for the third straight session on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Tenaya Therapeutics Announces TN-201 IND Clearance And Anticipated 2023 Milestones
9 Jan 23
Phase 1b Clinical Trial for TN-201 in MYBPC3-associated HCM Patients Expected to Begin Dosing in Third Quarter 2023; Data Anticipated in 2024 Data from First-in-Human Clinical Trial of TN-301 Anticipated
Tenaya Therapeutics Receives Orphan Drug Designation From FDA For Gene Therapy For Genetic Arrhythmogenic Right Ventricular Cardiomyopathy
28 Nov 22
12 Health Care Stocks Moving In Friday's Pre-Market Session
25 Nov 22

Press releases

From Benzinga Pro
Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors
7 Dec 22
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative
Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy
28 Nov 22
TN-401 is being developed for the treatment of genetic arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by mutations in the PKP2 gene Orphan Drug Designation for TN-401 is the first for a gene therapy
Thinking about buying stock in Canoo, Tenaya Therapeutics, Manchester United, Draganfly, or Meta Materials?
25 Nov 22
NEW YORK, Nov. 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GOEV, TNYA, MANU, DPRO, and MMAT.
Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference
23 Nov 22
Tenaya Therapeutics Announces Closing of Public Offering
21 Nov 22
Finsight
Resources
  • Knowledgebase
  • Log In
  • Register
Company
  • About
  • Contact
  • Solutions
Products
  • Deal Roadshow
  • DealVDR
  • Evercall
  • Finsight.com
CapEdge
  • Earnings Calendar
  • Earnings Transcripts
  • EDGAR Filing Screener
  • IPO Calendar
  • Compliance
  • Privacy
  • Security
  • Terms
AngelList LinkedIn